Table 1.
Patient characteristics (N = 58)
| Age (years) | Mean | 60.2 |
| Range | 32-83 | |
| Gender | Men | 36 |
| Women | 22 | |
| PS | 0 | 28 |
| 1 | 22 | |
| 2 | 6 | |
| 3 | 2 | |
| Adjuvant chemotherapy | No | 41 |
| Yes | 17 | |
| Primary tumor localization | Right colon | 6 |
| Left colon | 30 | |
| Rectum | 21 | |
| Unknown | 1 | |
| Metastasis characteristics | Single | 23 |
| Multiple | 35 | |
| Synchronous | 36 | |
| Metachronous | 22 | |
| KRAS mutation status | Non-mutated | 34 |
| Mutated at codon 12 or 13 | 16 | |
| Unknown | 8 | |
| Previous administration of bevacizumab for metastatic disease | No | 45 |
| Yes | 13 | |
| Line of cetuximab treatment | First | 1 |
| Second | 8 | |
| Third | 32 | |
| ≥ 4th | 17 | |
| Chemotherapy associated with cetuximab | None | 2 |
| Irinotecan | 41 | |
| FOLFIRI | 14 | |
| FOLFOX | 1 | |
| Number of cetuximab cycles | Mean | 7.6 |
| Median | 6.0 | |
| Range | 1-29 |